Today, the FDA granted traditional approved to lecanemab (branded as Leqembi), a monoclonal antibody from Eisai and Biogen for adult patients with Alzheimer’s disease. The agency made the decision on the basis of a confirmatory trial that showed its clinical benefit. The drug, which reduces the formation of amyloid plaques in the brain, is the…

The COVID-19 pandemic has contributed to a significant increase in the rates of Americans living with mental illness.1 Meanwhile, medication shortages and a chronic scarcity of mental health professionals added pressure to an already stressed system.2 In this context, pharma companies play a vital role in developing novel therapies for mental health conditions, which can…

Now that it has been nearly four months since the FDA authorized the first COVID-19 vaccine, a considerable amount of safety information is available about the Pfizer-BioNTech vaccine. CDC recently released a summary of adverse event data related to the Pfizer-BioNTech vaccine based on more than 5,000 entries to the Vaccine Adverse Event Reporting System collected…